In the study, which was published in JACC: Cardiovascular Interventions, Mayo Clinic researchers applied the algorithm to a retrospective analysis of data from the Rochester, Minn.-based medical center’s PCI registry. The information included EHR, demographic and social data from nearly 12,000 Mayo Clinic patients, who had collectively undergone more than 14,000 PCIs.
As a result, compared to standard regression methods, the algorithm was proven to be a better predictor of mortality 180 days post-PCI and of 30-day rehospitalization for congestive heart failure. Additionally, the algorithm successfully identified patient subgroups at an elevated risk of other post-PCI complications and readmission.
Medial EarlySign has developed several other machine learning-powered solutions. Most recently, the company partnered with Danville, Pa.-based Geisinger to develop and deploy a suite of new solutions to assess patients’ risk of contracting various high-burden diseases.
More articles on AI:
‘AI hesitancy’ is hindering the potential of medical chatbots, study finds
Mayo Clinic researchers develop AI to measure physiological health from ECG
Physician viewpoint: AI needs a ‘Turing test’ to determine medical feasibility
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
